Showing results (131-140 of 352) with videos related to
Sort By:
Pageof 36
Open Forum Infectious Diseases|May 22, 2023
Respiratory Syncytial Virus-Related Complications and Healthcare Costs Among a Medicare-Insured Population in the United StatesJessica K DeMartino, Marie-Hélène Lafeuille, Bruno Emond, et al.Current Medical Research and Opinion|May 28, 2020
An assessment of weight change associated with the initiation of a protease or integrase strand transfer inhibitor in patients with human immunodeficiency virusWing Chow, Prina Donga, Aurélie Côté-Sergent, et al.Journal of Medical Economics|April 29, 2021
Healthcare resource utilization and costs of rivaroxaban versus warfarin among non-valvular atrial fibrillation (NVAF) patients with obesity in a US populationJeffrey S Berger, François Laliberté, Akshay Kharat, et al.Journal of Comparative Effectiveness Research|February 9, 2019
Medicaid spending burden among beneficiaries with treatment-resistant depressionDominic Pilon, John J Sheehan, Holly Szukis, et al.Journal of the Neurological Sciences|May 8, 2013
Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregiversHélène Parisé, François Laliberté, Patrick Lefebvre, et al.Pharmacoeconomics|October 26, 2013
Systematic literature review of the costs of pregnancy in the USLynn Huynh, Mark McCoy, Amy Law, et al.Current Medical Research and Opinion|August 6, 2024
Comparison of real-world healthcare resource utilization among advanced therapy-naïve and advanced therapy-experienced patients with ulcerative colitis initiated on ustekinumab or vedolizumabMaryia Zhdanava, Sumesh Kachroo, Porpong Boonmak, et al.Journal of Managed Care & Specialty Pharmacy|July 1, 2024
Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United StatesDeborah R Kaye, Ibrahim Khilfeh, Erik Muser, et al.The Journal of Dermatological Treatment|May 15, 2024
Comparative analysis of persistence and remission with guselkumab <i>versus</i> secukinumab and ixekizumab in the United StatesMaryia Zhdanava, Timothy Fitzgerald, Dominic Pilon, et al.Current Medical Research and Opinion|November 23, 2021
Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United StatesBruno Emond, Carmine Rossi, Aurélie Côté-Sergent, et al.Pageof 36